Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0457 Transporter Info
Gene Name SLC6A5
Transporter Name Sodium- and chloride-dependent glycine transporter 2
Gene ID
9152
UniProt ID
Q9Y345
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Arsenic Trioxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic Trioxide increases the expression of SLC6A5 [1]

  Testosterone undecanoate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone undecanoate increases the expression of SLC6A5 [2]

  Atomoxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atomoxetine inhibits the activity of SLC6A5 [3] , [4]

  Tramadol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tramadol inhibits the activity of SLC6A5 [5]

  Amitriptyline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitriptyline inhibits the activity of SLC6A5 [6]

  Desipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the activity of SLC6A5 [7] , [8]

  Cocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine induces the activity of SLC6A5 [9] , [10]

  Sibutramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sibutramine inhibits the activity of SLC6A5 [11]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat induces the activity of SLC6A5 [12]

  Duloxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Duloxetine inhibits the activity of SLC6A5 [13] , [14]

Investigative Drug

  ALX 1393

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 ALX 1393 inhibits the activity of SLC6A5 [16]

Fungicide

  Tebuconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tebuconazole inhibits the expression of SLC6A5 [15]
References
1 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
2 Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. Biol Reprod. 2009 Mar;80(3):484-92.
3 A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009 Aug;34(9):2135-42.
4 Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7.
5 Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6.
6 A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception. Neuroscience. 2011 Feb 23;175:315-27.
7 Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000 Aug;57(8):787-93.
8 Tyrosine depletion lowers dopamine synthesis and desipramine-induced prefrontal cortex catecholamine levels. Brain Res. 2008 Jan 23;1190:39-48.
9 Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity in the bed nucleus of the stria terminalis of the rhesus monkey. J Neurosci. 2003 Jan 1;23(1):12-6.
10 Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry. 1998 Sep;55(9):793-9.
11 Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3.
12 Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15;17(8):2339-49.
13 Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab. 2011 Sep;96(9):2844-50.
14 Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. J Pharmacol Exp Ther. 2012 Apr;341(1):137-45.
15 The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway. Food Chem Toxicol. 2019 Jan;123:481-491.
16 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 936).

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.